Physician profile
Andrea M Ely
NPI 1184734816
$1,385.95
in general payments reported to CMS, 2019-2025
22 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.21 · 2020: $170 · 2021: $140 · 2022: $410 · 2023: $284 · 2024: $196 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.04 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $570.29 | 2021-2025 | |
| Novo Nordisk INC | $105.03 | 2019-2023 | Ozempic, Rybelsus |
| Allergan, INC. | $80.62 | 2020 | |
| Astellas Pharma US INC | $79.46 | 2022-2025 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $67.59 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $59.20 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $58.65 | 2022-2025 | Repatha, Otezla |
| Pfizer INC. | $54.64 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $44.52 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $38.88 | 2021-2024 | Capvaxive, Vaxneuvance, Gardasil |
| Glaxosmithkline, LLC. | $31.52 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.65 | 2024 | Trintellix |
| Averitas Pharma INC. | $25.21 | 2023 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $22.51 | 2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $17.52 | 2025 | Eliquis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.34 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.15 | 2022 | |
| Lilly USA, LLC | $15.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.43 | 2020 | |
| Mylan Specialty L.P. | $14.01 | 2021 | |
| Esperion Therapeutics, INC. | $13.76 | 2020 | |
| Nabriva Therapeutics, Plc | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.